These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 33072137)

  • 21. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
    Lucca LE; Hafler DA
    Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
    Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
    Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer.
    Opzoomer JW; Sosnowska D; Anstee JE; Spicer JF; Arnold JN
    Front Immunol; 2019; 10():1654. PubMed ID: 31379850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging strategies in regulatory T-cell immunotherapies.
    Gajewski TF; Chesney J; Curriel TJ
    Clin Adv Hematol Oncol; 2009 Jan; 7(1):1-10; quiz 11-2. PubMed ID: 19288606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
    Take Y; Koizumi S; Nagahisa A
    Front Immunol; 2020; 11():324. PubMed ID: 32210957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.
    Klevorn LE; Berrien-Elliott MM; Yuan J; Kuehm LM; Felock GD; Crowe SA; Teague RM
    Cancer Immunol Res; 2016 Dec; 4(12):1016-1026. PubMed ID: 27803062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy.
    Chuckran CA; Liu C; Bruno TC; Workman CJ; Vignali DA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32675311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T cell tolerance to tumors and cancer immunotherapy.
    Shafer-Weaver K; Anderson M; Malyguine A; Hurwitz AA
    Adv Exp Med Biol; 2007; 601():357-68. PubMed ID: 17713024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint blockade therapy.
    Wieder T; Eigentler T; Brenner E; Röcken M
    J Allergy Clin Immunol; 2018 Nov; 142(5):1403-1414. PubMed ID: 29596939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors.
    Derer A; Frey B; Fietkau R; Gaipl US
    Cancer Immunol Immunother; 2016 Jul; 65(7):779-86. PubMed ID: 26590829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.
    Makkouk A; Weiner GJ
    Cancer Res; 2015 Jan; 75(1):5-10. PubMed ID: 25524899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.
    Berrien-Elliott MM; Yuan J; Swier LE; Jackson SR; Chen CL; Donlin MJ; Teague RM
    Cancer Immunol Res; 2015 Feb; 3(2):116-24. PubMed ID: 25516478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
    Bertaina A; Roncarolo MG
    Front Immunol; 2019; 10():1342. PubMed ID: 31354695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of T-cell inhibition: implications for cancer immunotherapy.
    Mittendorf EA; Sharma P
    Expert Rev Vaccines; 2010 Jan; 9(1):89-105. PubMed ID: 20021308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T cell recognition of human tumors: implications for molecular immunotherapy of cancer.
    Ioannides CG; Whiteside TL
    Clin Immunol Immunopathol; 1993 Feb; 66(2):91-106. PubMed ID: 8453790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer.
    Jørgensen N; Persson G; Hviid TVF
    Front Immunol; 2019; 10():911. PubMed ID: 31134056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immune tolerance and active suppression in oncology. Immunological principles and therapeutic options].
    Stremmel C; Klein P; Hohenberger W
    Chirurg; 2002 Mar; 73(3):255-61. PubMed ID: 11963500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Basics of cancer immunotherapy].
    Fujioka Y; Nishikawa H
    Rinsho Ketsueki; 2016; 57(11):2346-2354. PubMed ID: 27941285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.